Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US00439U1043
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG001NMDXS6
GRCE

Grace Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Grace Therapeutics, Inc.
ISIN
US00439U1043
TICKER
GRCE
MIC
XNAS
REUTERS
GRCE.OQ
BLOOMBERG
GRCE US
Wed, 05.08.2026       Grace Therapeutics

Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028...
Tue, 28.07.2026       Grace Therapeutics

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data...
Thu, 18.06.2026       Grace Therapeutics

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission...
Wed, 27.05.2026       Grace Therapeutics

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (“Grace” or “the Company”) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to d...
Thu, 21.05.2026       Grace Therapeutics

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Fri, 15.05.2026       Grace Therapeutics

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Thu, 23.04.2026       Grace Therapeutics

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information ...
Tue, 14.04.2026       Grace Therapeutics

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarach...
Wed, 25.02.2026       Grace Therapeutics

PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemo...
Thu, 12.02.2026       Grace Therapeutics

FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)...
Silent Ad
Thu, 13.11.2025       Grace Therapeutics

Announced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104...
Tue, 11.11.2025       Grace Therapeutics

STRIVE-ON Results Accepted for Late-Breaking Presentation STRIVE-ON Results Accepted for Late-Breaking Presentation...
Thu, 18.09.2025       Grace Therapeutics

Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection...
Thu, 04.09.2025       Grace Therapeutics

PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announc...
Tue, 12.08.2025       Grace Therapeutics

Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)...
Mon, 23.06.2025       Grace Therapeutics

Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements...
Fri, 13.06.2025       Grace Therapeutics

PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemor...
Thu, 13.02.2025       Grace Therapeutics

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025...
Mon, 10.02.2025       Grace Therapeutics

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors...
Mon, 10.02.2025       Grace Therapeutics

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine...
Silent Ad
Tue, 07.01.2025       Grace Therapeutics

PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal suba...
Wed, 13.11.2024       Grace Therapeutics

STRIVE-ON Data Readout Expected First Calendar Quarter 2025; NDA Submission on Track for 1H Calendar 2025...
Wed, 09.10.2024       Grace Therapeutics

Instrument ID [21219368] (L8S - US00439U1043) suspended...